Market Cap 13.33M
Revenue (ttm) 41.71M
Net Income (ttm) -10.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -25.27%
Debt to Equity Ratio 0.44
Volume 464,000
Avg Vol 142,484
Day's Range N/A - N/A
Shares Out 12.01M
Stochastic %K 14%
Beta 0.89
Analysts Strong Sell
Price Target $6.00

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 245 1325
Address:
660 Main Street, 1st Floor, Woburn, United States
Killllin
Killllin May. 12 at 4:04 PM
$BFRI cut my losses ……… I was here for almost 2yrs but If you sparkle again someday, I’ll come back
0 · Reply
ivo98
ivo98 May. 11 at 6:17 PM
$BFRI they will pump it after ER and then offering. They need cash. No profit Q1 🤔🤣
1 · Reply
Polaris2024
Polaris2024 May. 8 at 11:57 PM
$BFRI we are up 24% in last month and the momentum is happening. Wait for the next news on the last quarter and it will break out upward again.
0 · Reply
Killllin
Killllin May. 5 at 1:38 PM
$BFRI today is the day ?
0 · Reply
GDS100
GDS100 May. 5 at 4:34 AM
$BFRI lets go 50 , its been long time
2 · Reply
Davb1231
Davb1231 May. 5 at 12:35 AM
$BFRI let’s go
0 · Reply
Stockseeking
Stockseeking May. 4 at 5:31 PM
$BFRI 2026 Q1 may turn things around, based on 2025 Q4, shown below
0 · Reply
BioSpecialOne
BioSpecialOne Apr. 28 at 3:06 PM
$BFRI The Phase 3 data for Ameluz sBCC is an absolute monster. We are talking 65.5% complete clearance versus just 4.8% for placebo with a p value of <0.0001. Even better, over 85% reported a good or very good aesthetic outcome. This is a massive label expansion and the FDA accepted the sNDA without a single question. PDUFA is locked for Sept 28. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
1 · Reply
BioSpecialOne
BioSpecialOne Apr. 28 at 3:01 PM
$BFRI It is no secret that the balance sheet is tight right now. Everyone is staring at the $6.4M cash pile and sitting on the sidelines waiting for an offering. But that fear is exactly why the stock is trading at such a massive discount. The market is completely ignoring the locked Sept 28 PDUFA date for Ameluz sBCC. This is not some speculative Phase 2 binary event; it is a major label expansion for a product that already generates real revenue. Yes, the cash needs to be addressed, but once that overhang is cleared, there is zero resistance stopping a massive pre PDUFA run up. Accumulating quietly while the retail crowd is asleep.
0 · Reply
InvestingSpaceman
InvestingSpaceman Apr. 27 at 10:42 PM
0 · Reply
Latest News on BFRI
Biofrontera Earnings Call Transcript: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 7 weeks ago

Biofrontera Earnings Call Transcript: Q4 2025


Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year

2026-03-19T13:36:56.000Z - 7 weeks ago

Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year


Biofrontera announces FDA acceptance of sNDA for Ameluz PDT

2026-02-11T14:20:35.000Z - 3 months ago

Biofrontera announces FDA acceptance of sNDA for Ameluz PDT


Biofrontera announces positive Phase 3 results for Ameluz PDT

2026-02-09T14:25:30.000Z - 3 months ago

Biofrontera announces positive Phase 3 results for Ameluz PDT


Biofrontera reports preliminary Q4 revenue $17M-$17.5M

2026-01-13T13:36:29.000Z - 4 months ago

Biofrontera reports preliminary Q4 revenue $17M-$17.5M


Biofrontera announces data base locks for two clinical studies

2026-01-08T14:01:20.000Z - 4 months ago

Biofrontera announces data base locks for two clinical studies


Biofrontera completes transfer of Ameluz, RhodoLED FDA approval

2025-12-18T13:51:20.000Z - 5 months ago

Biofrontera completes transfer of Ameluz, RhodoLED FDA approval


Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC

2025-12-02T13:50:16.000Z - 5 months ago

Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC


Biofrontera Earnings Call Transcript: Q3 2025

Nov 13, 2025, 10:00 AM EST - 6 months ago

Biofrontera Earnings Call Transcript: Q3 2025


Biofrontera reports Q3 EPS (62c) vs (98c) last year

2025-11-13T13:21:24.000Z - 6 months ago

Biofrontera reports Q3 EPS (62c) vs (98c) last year


Biofrontera Earnings Call Transcript: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 9 months ago

Biofrontera Earnings Call Transcript: Q2 2025


Biofrontera Earnings Call Transcript: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q1 2025


Biofrontera Earnings Call Transcript: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q4 2024


Biofrontera Earnings Call Transcript: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Earnings Call Transcript: Q3 2024


Biofrontera Earnings Call Transcript: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q2 2024


Biofrontera Earnings Call Transcript: Q1 2024

May 16, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings Call Transcript: Q1 2024


Killllin
Killllin May. 12 at 4:04 PM
$BFRI cut my losses ……… I was here for almost 2yrs but If you sparkle again someday, I’ll come back
0 · Reply
ivo98
ivo98 May. 11 at 6:17 PM
$BFRI they will pump it after ER and then offering. They need cash. No profit Q1 🤔🤣
1 · Reply
Polaris2024
Polaris2024 May. 8 at 11:57 PM
$BFRI we are up 24% in last month and the momentum is happening. Wait for the next news on the last quarter and it will break out upward again.
0 · Reply
Killllin
Killllin May. 5 at 1:38 PM
$BFRI today is the day ?
0 · Reply
GDS100
GDS100 May. 5 at 4:34 AM
$BFRI lets go 50 , its been long time
2 · Reply
Davb1231
Davb1231 May. 5 at 12:35 AM
$BFRI let’s go
0 · Reply
Stockseeking
Stockseeking May. 4 at 5:31 PM
$BFRI 2026 Q1 may turn things around, based on 2025 Q4, shown below
0 · Reply
BioSpecialOne
BioSpecialOne Apr. 28 at 3:06 PM
$BFRI The Phase 3 data for Ameluz sBCC is an absolute monster. We are talking 65.5% complete clearance versus just 4.8% for placebo with a p value of <0.0001. Even better, over 85% reported a good or very good aesthetic outcome. This is a massive label expansion and the FDA accepted the sNDA without a single question. PDUFA is locked for Sept 28. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
1 · Reply
BioSpecialOne
BioSpecialOne Apr. 28 at 3:01 PM
$BFRI It is no secret that the balance sheet is tight right now. Everyone is staring at the $6.4M cash pile and sitting on the sidelines waiting for an offering. But that fear is exactly why the stock is trading at such a massive discount. The market is completely ignoring the locked Sept 28 PDUFA date for Ameluz sBCC. This is not some speculative Phase 2 binary event; it is a major label expansion for a product that already generates real revenue. Yes, the cash needs to be addressed, but once that overhang is cleared, there is zero resistance stopping a massive pre PDUFA run up. Accumulating quietly while the retail crowd is asleep.
0 · Reply
InvestingSpaceman
InvestingSpaceman Apr. 27 at 10:42 PM
0 · Reply
Tboonepickem
Tboonepickem Apr. 23 at 11:34 AM
$BFRI What was that little tease about? 1.14 at PM opening. God forbid this would ever hit 1.20 🤪
0 · Reply
mmtiddy
mmtiddy Apr. 20 at 12:17 PM
$BFRI To protect my gains, I sold some shares, I might revisit later
2 · Reply
LION86
LION86 Apr. 17 at 9:15 PM
$BFRI they push it up over one dollars for ten consecutive days, after that it will come under one dollars again… but anyway I will keep it…
0 · Reply
mmtiddy
mmtiddy Apr. 17 at 3:39 PM
$BFRI I bought this around $0.80, still holding, what’s the move? We holding? Chopping positions? It’s at a very critical point now, if it breaks this strong resistance of $1.20 it can fly well, but if volume starts drying up we may see it go down again
1 · Reply
BioSpecialOne
BioSpecialOne Apr. 17 at 1:10 PM
$BFRI I'm in for pre PDUFA run. Hope they will not dillute much before.
0 · Reply
BioSpecialOne
BioSpecialOne Apr. 16 at 11:23 AM
$BFRI Deep dive into the financial cycle: Despite a record Q4 2025 and new U.S. Ameluz rights significantly improving gross margins , the balance sheet needs attention. As of March 11, 2026, unaudited cash stood at just $3.6M , against a 2025 operating cash burn of $13.4M. With the Q1 report approaching, the company needs capital to maintain its runway and alleviate ongoing "going concern" risks. Investors should note the active $100M ATM facility with B. Riley, which still has over $98M in capacity. Historically, the company raises capital when cash dips below the $3M-$4M mark. Instead of a sudden offering, we might see continuous, quiet dilution through the ATM during high-volume price action. This mechanism allows them to smoothly bridge the funding gap toward their upcoming Sept 2026 PDUFA date for sBCC
0 · Reply
Stereo
Stereo Apr. 15 at 10:14 PM
$BFRI has been very tame in their dilution practices. When they took on initial litigation they diluted from 5.54mil shares to 7.75mil over 3 months, then 7.75mil to 8.87mil over another 3 months, then 8.87mil to 9.45mil over 3 months, then 9.45mil to 10.67mil over 3 months, then 10.67mil to 11.65mil over 3 months. What this says to me as a shareholder is that their dilution practices are strictly a means of survival quarter to quarter. If they were to dilute to 13-16mil shares or so I would not be bothered given they are on the cusp of breakeven. Given their current complex share structure full dilution stands around ~46mil or so right now. All this being said, so long as their common shares do no exceed to dilute beyond 25mil shares by breakeven, I think we are in good standing. If the stock re-rates higher post-PDUFA or they secure better terms/non-dilutive options that would be ideal to reducing new-share issuance.
1 · Reply
BioSpecialOne
BioSpecialOne Apr. 15 at 7:18 PM
$BFRI I Putting the obvious offering risk aside for a second, the tactical setup here has all the exact ingredients for a violent pre PDUFA run up. First the cap structure. Institutional ownership is extremely low. That means no heavy resistance ceilings. The float is tight and any real retail volume will send the price flying. Second the clinical narrative. 76 percent histological clearance versus 19 percent for placebo. That is the exact type of data that builds massive hype. Third the legal moat. The asset is secured. Patent protected until 2043 and they just defeated Sun Pharma. Finally the growth metrics. Record Q4 revenues jumping 36 percent with 82 percent gross margins.
0 · Reply
BioSpecialOne
BioSpecialOne Apr. 15 at 3:05 PM
$BFRI anyone?
0 · Reply
BioSpecialOne
BioSpecialOne Apr. 15 at 9:40 AM
$BFRI The clinical data here is solid and I am tempted to join the run up. But looking at the balance sheet this is a ticking time bomb for an offering. They need cash immediately and a toxic dilution could drop at any second. For the bulls holding right now: how are you justifying the massive offering risk while waiting for the PDUFA?
0 · Reply
AlTryToTrade
AlTryToTrade Apr. 9 at 7:41 PM
0 · Reply
Timothyb
Timothyb Apr. 6 at 7:14 PM
0 · Reply